Tipsheet
What matters at India’s listed companies
Earnings · Agrochemicals · Small cap

Rallis India Q1 PAT climbs 31% to ₹125 cr on broad-based growth

Revenue rose 7% to ₹1,022 crore, led by a 19% jump in domestic B2C. Seeds revenue up 6% on new hybrid launches. But the quarterly release is a routine event with no surprise strategic moves.

3 earlier stories on Rallis India Ltd.
Mkt cap₹4,425 cr
P/E24.06×
ROE9.00%
Debt / eq.0.00
Div yld1.30%
31% PAT growth YoY

What's new

  • Revenue up 7% to ₹1,022 cr, PAT up 31% to ₹125 cr.
  • Crop care B2C grew 19%; contract manufacturing exports declined.
  • Seeds revenue rose 6% to ₹325 cr on nine new hybrid launches.
  • Soil & plant health segment expanded 10% aided by new fertilisers.

Why this matters

The 31% PAT growth reflects disciplined pricing and portfolio strength, but this is a routine quarterly earnings release. The market already prices in seasonal variance; no unexpected strategic development here to move the stock materially.

What we're watching

  • Sustainability of B2C momentum amid agro-price volatility.
  • Outlook for contract manufacturing exports — currently a drag.
  • Next catalysts: monsoon progress and new product adoption.

The full read

Rallis India lifted PAT 31% to ₹125 crore in Q1 FY27. Revenue climbed 7% to ₹1,022 crore. The domestic B2C crop care segment jumped 19%, while seeds revenue rose 6% to ₹325 crore on nine new hybrid launches. Solid. The soil and plant health segment added 10%. These results show disciplined pricing and portfolio investments paying off. But this is a routine quarterly release; the market already prices in seasonal variance. There is no unexpected strategic move here. At a P/E of 24.1 and debt-free balance sheet, the valuation reflects steady expectations. The next test is whether B2C momentum can hold if agro-commodity prices soften.

Questions answered

What drove the 31% PAT growth despite only 7% revenue growth?
Margin expansion from disciplined pricing and portfolio mix improvements, plus cost optimisation, lifted profit faster than revenue.
Which segment contributed most to the revenue growth?
The crop care domestic B2C segment grew 19%, offsetting a decline in contract manufacturing exports.
How did the seeds business perform?
Seeds revenue rose 6% to ₹325 crore, helped by the launch of nine new hybrids across cotton, paddy, and millet.
Is the soil & plant health segment significant?
It grew 10% supported by biostimulants and new fertilisers, but its absolute contribution is smaller than crop care and seeds.
Why is this result considered routine?
The earnings are in line with expectations and lack a strategic surprise (e.g., no major order or M&A), so stock reaction is likely muted.
Mentioned: Rallis India · ₹1,022 cr revenue · ₹125 cr PAT
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Rallis India Ltd.

Agrochemicals
₹4,671 cr
P/E 25.40×

Latest quarter · Mar 2022

Sales₹508 cr
Net profit−₹14 cr
Op. margin−0.6%
EPS−₹0.73

Strength & growth

Debt / equity0.03×
Current ratio1.66×
Sales CAGR+6.5%
EPS CAGR−4.2%
Financials via Tijori — a research aid, not investment advice.RALLIS on Tijori
  1. 20 Jul 2026 · 8:18 PM IST Rallis India Q1 PAT climbs 31% to ₹125 cr on broad-based growth
  2. today Rallis India pulls back on seed growth, pricing pass-through weakens
  3. 1d ago Rallis India profit jumps 32% on ₹35 cr one-time boost
  4. 1d ago Rallis Q1 profit up 32%, but the story is déjà vu